BALTIMORE, May 30, 2017 – Elixirgen Therapeutics has successfully concluded its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for inherited bone marrow failure syndromes (IBMFS), including Dyskeratosis Congenita (DC) and Fanconi Anemia (FA).
BALTIMORE, January 5, 2017 – Elixirgen, LLC announced that it has formed its therapeutics-focused subsidiary company, Elixirgen Therapeutics, LLC, on January 5, 2017. Elixirgen Therapeutics is a company that is dedicated to finding cures and therapies for genetic diseases, and then developing them into drugs to treat patients. The company’s experienced team of researchers has a wide […]
BALTIMORE, August 5, 2016 – Elixirgen has awarded the Small Business Innovation Research (SBIR) Phase I Grant from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH).